Navigation Links
Intravenous gene therapy protects normal tissue of mice during whole-body radiation
Date:10/28/2007

LOS ANGELES, Oct. 28 Gene therapy administered intravenously could be an effective agent to protect vital organs and tissues from the effects of ionizing radiation in the event of large-scale exposure from a radiological or nuclear bomb, according to an animal study presented today by University of Pittsburgh researchers at the 49th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Los Angeles.

Ionizing radiation can be extremely damaging to cells, tissues, organs and organ systems, said Joel S. Greenberger, M.D., professor and chairman, department of radiation oncology, University of Pittsburgh School of Medicine. In previous studies, we demonstrated that gene therapy can be both swallowed in liquid form and inhaled through a nebulizer prior to radiation exposure to protect healthy tissues from damage. In this study, we found that the same therapy administered intravenously also offers protection during exposure to whole-body irradiation. Dr. Greenberger added that intravenous administration could potentially offer wide-reaching protection to the public in the event of a terrorist attack since experts believe a significant number of the population would die within 30 days of receiving a large dose of radiation to the entire body.

In the study, mice were used to test the protective effects of manganese superoxide dismutase plasmid liposome (MnSOD-PL) gene therapy on the bone marrow during whole-body irradiation. The researchers found that in a control group of mice that received an initial 9.5 Gy dose of radiation, 58 percent survived at 30 days compared to 90 percent after the same length of time for an experimental group of mice that were injected with MnSOD-PL prior to irradiation. Between 30 and 330 days, there were no differences in survival rates between experiment and control group mice, indicating that systemic MnSOD-PL treatment was not harmful to survival.

Intravenous administration of gene therapy appears to prevent the damaging effects of radiation, suggesting it is a viable delivery method, said Dr. Greenberger. Future clinical studies will tell us whether this therapy can protect people from the deadly effects of radiation.


'/>"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
2. Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer
3. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Gene therapy converts dead bone graft to new, living tissue
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. Gene Therapy For Parkinsons Disease Moves Forward In Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology: